Nanolevel Immunomodulators in Sepsis: Novel Roles, Current Perspectives, and Future Directions

Int J Nanomedicine. 2024 Nov 23:19:12529-12556. doi: 10.2147/IJN.S496456. eCollection 2024.

Abstract

Sepsis represents a profound challenge in critical care, characterized by a severe systemic inflammatory response which can lead to multi-organ failure and death. The intricate pathophysiology of sepsis involves an overwhelming immune reaction that disrupts normal host defense mechanisms, necessitating innovative approaches to modulation. Nanoscale immunomodulators, with their precision targeting and controlled release capabilities, have emerged as a potent solution to recalibrate immune responses in sepsis. This review explores the recent advancements in nanotechnology for sepsis management, emphasizing the integration of nanoparticulate systems to modulate immune function and inflammatory pathways. Discussions detail the development of the immune system, the distinct inflammatory responses triggered by sepsis, and the scientific principles underpinning nanoscale immunomodulation, including specific targeting mechanisms and delivery systems. The review highlights nanoformulation designs aimed at enhancing bioavailability, stability, and therapeutic efficacy, which shows promise in clinical settings by modulating key inflammatory pathways. Ultimately, this review synthesizes the current state of knowledge and projects future directions for research, underscoring the transformative potential of nanolevel immunomodulators for sepsis treatment through innovative technologies and therapeutic strategies.

Keywords: Nanomedicine; extracellular vesicles; immunomodulator; review; sepsis.

Publication types

  • Review

MeSH terms

  • Animals
  • Humans
  • Immunologic Factors* / chemistry
  • Immunologic Factors* / pharmacology
  • Immunologic Factors* / therapeutic use
  • Immunomodulating Agents / chemistry
  • Immunomodulating Agents / pharmacology
  • Immunomodulation / drug effects
  • Nanomedicine / methods
  • Nanoparticles* / chemistry
  • Sepsis* / drug therapy
  • Sepsis* / immunology

Substances

  • Immunologic Factors
  • Immunomodulating Agents

Grants and funding

This research was supported by the National Key Research and Development Project (No. 2021YFC2701705).